This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In light of the growing number of patients undergoing transcatheter aortic valve replacement (TAVR), there is an increasing demand for data regarding the management of failed TAVR procedures, including the possibility of a repeat TAVR intervention. vs. 19.0%, p=0.57), as well as stroke at 30 days (2.0%
Transcatheter Mitral Valve Repair is Cost-Effective in Heart Failure Patients TAVR Expected to See Rapid Growth in Next 5 years FDA Clears Abbott Amplatzer Amulet LAA Occluder to Reduce Stroke in People With Atrial Fibrillation Portico TAVR System Found Safe and Effective for High-Risk Surgical Patients Portico TAVR System Reduces Severe (..)
According to the Centers for Disease Control and Prevention (CDC), heart disease and stroke rank as the first and fifth leading causes of death in the nation. About 276,000 patients have undergone a TAVR procedure in the United States. PAD contributes to 400 amputations each day.
The SMART trial is the first randomized head-to-head comparison of the two most widely used TAVR devices—the supra-annular self-expanding Evolut PRO/PRO+/FX and the balloon-expandable SAPIEN 3/3 Ultra. percentage points—in one-year bioprosthetic valve dysfunction favoring the Evolut platform. of those receiving the SAPIEN valve.
A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aortic valve replacement (TAVR) using Evolut TAVR compared to surgical aortic valve replacement (SAVR) for low-risk patients. At Medtronic, we continue to emphasize that valve design matters. healthcare system perspective.
Part 1: Concepts, Indicator Variables, and Controversies The Annals of Thoracic Surgery January 2022 Arman Kilic Supplementing Existing Societal Risk Models for Surgical Aortic Valve Replacement With Machine Learning for Improved Prediction Journal of the American Heart Association November 2021 Jared Belle Strategies for Mechanical Right Ventricular (..)
Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori 1 Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion 2 Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content